| Autor: |
Kaul K; Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, University of Exeter & Plymouth, St Luke's Campus, Exeter EX1 2LU, UK., Hodgkinson A, Tarr JM, Kohner EM, Chibber R |
| Jazyk: |
angličtina |
| Zdroj: |
Current diabetes reviews [Curr Diabetes Rev] 2010 Sep; Vol. 6 (5), pp. 294-303. |
| DOI: |
10.2174/157339910793360851 |
| Abstrakt: |
The global diabetes burden is predicted to rise to 380 million by 2025 and would present itself as a major health challenge. However, both Type 1 and Type 2 diabetes increase the risk of developing micro-vascular complications and macro-vascular complications which in turn will have a devastating impact on quality of life of the patients and challenge health services Worldwide. The micro-vascular complications that affect small blood vessels are the leading cause of blindness (diabetic retinopathy) in the people of the working-age, end-stage renal disease (diabetic nephropathy) the most common cause of kidney failure today, and foot amputation (diabetic neuropathy) in patients with Type 1 and Type 2 diabetes. It is accepted that hyperglycemia is a major causative factor for the development of these complications, there is also growing evidence for the role of inflammation. Here we discuss low-grade inflammation as a common retinal-renal-nerve pathogenic link in patients with Type 1 and Type 2 diabetes. This review summarizes evidence showing a link between circulating and locally produced inflammatory biomarkers, such as cell adhesion molecules (vascular adhesion cell molecule-1, VCAM-1; intracellular adhesion molecule-1, ICAM-1), pro-inflammatory cytokines (interleukin-6, IL-6; tumour necrosis factor-alpha, TNF-α; C-reactive protein, CRP) with the development and progression of diabetic micro-vascular complications. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
